These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23374223)

  • 1. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells.
    Malavaki CJ; Roussidis AE; Gialeli C; Kletsas D; Tsegenidis T; Theocharis AD; Tzanakakis GN; Karamanos NK
    FEBS J; 2013 May; 280(10):2477-89. PubMed ID: 23374223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.
    Yamaguchi SI; Ueki A; Sugihara E; Onishi N; Yaguchi T; Kawakami Y; Horiuchi K; Morioka H; Matsumoto M; Nakamura M; Muto A; Toyama Y; Saya H; Shimizu T
    Cancer Sci; 2015 Jul; 106(7):875-82. PubMed ID: 25940371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
    Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
    Schultz JD; Rotunno S; Riedel F; Anders C; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
    Int J Oncol; 2011 Apr; 38(4):1001-12. PubMed ID: 21249316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
    J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
    J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.
    Abouantoun TJ; MacDonald TJ
    Mol Cancer Ther; 2009 May; 8(5):1137-47. PubMed ID: 19417143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects.
    Rocha A; Azevedo I; Soares R
    J Cell Biochem; 2008 Feb; 103(2):607-14. PubMed ID: 17614352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.
    Aoki M; Nabeshima K; Koga K; Hamasaki M; Suzumiya J; Tamura K; Iwasaki H
    Lab Invest; 2007 Aug; 87(8):767-79. PubMed ID: 17558420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1α depletion or imatinib treatment.
    Veith C; Zakrzewicz D; Dahal BK; Bálint Z; Murmann K; Wygrecka M; Seeger W; Schermuly RT; Weissmann N; Kwapiszewska G
    Thromb Haemost; 2014 Dec; 112(6):1288-303. PubMed ID: 25231004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
    Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
    Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
    Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes.
    Kadivar A; Kamalidehghan B; Akbari Javar H; Karimi B; Sedghi R; Noordin MI
    Drug Des Devel Ther; 2017; 11():469-481. PubMed ID: 28260860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
    Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
    Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
    Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Kit and platelet-derived growth factor receptors alpha and beta in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571).
    Holcombe RF; Gu M; Imagawa D; Milovanovic T
    Anticancer Drugs; 2003 Sep; 14(8):651-7. PubMed ID: 14501388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.
    Perros F; Montani D; Dorfmüller P; Durand-Gasselin I; Tcherakian C; Le Pavec J; Mazmanian M; Fadel E; Mussot S; Mercier O; Hervé P; Emilie D; Eddahibi S; Simonneau G; Souza R; Humbert M
    Am J Respir Crit Care Med; 2008 Jul; 178(1):81-8. PubMed ID: 18420966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma.
    Kodama M; Kitadai Y; Sumida T; Ohnishi M; Ohara E; Tanaka M; Shinagawa K; Tanaka S; Yasui W; Chayama K
    Cancer Sci; 2010 Sep; 101(9):1984-9. PubMed ID: 20624165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
    Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.